NCT05672537 2023-01-05
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
Tianjin Medical University Cancer Institute and Hospital
First Affiliated Hospital, Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University